Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

e-Therapeutics Starts Second Phase I Cancer Trial of ETS2101

Published: Friday, February 01, 2013
Last Updated: Friday, February 01, 2013
Bookmark and Share
Trial will enrol up to 45 patients with solid tumours at UK centres.

e-Therapeutics plc has announced that it has started a second phase I clinical trial of its anti-cancer drug ETS2101. This trial will enrol up to 45 patients with a variety of solid tumours at two UK centres, St James’s University Hospital in Leeds and the Northern Centre for Cancer Care at the Freeman Hospital in Newcastle.

It complements an investigator-led phase I study of ETS2101 in brain cancer that began in San Diego, California during June.

Like the brain cancer study, the UK trial has a dose-escalating design in which groups of patients receive successively higher doses of the drug.

The primary objective is to evaluate the safety of ETS2101 and identify an appropriate dose for phase II development. Secondary objectives include initial assessment of the drug’s activity and evaluation of its distribution within the body (pharmacokinetics). Final results from the trial are expected during 2013.

Professor Ruth Plummer, Clinical Professor of Experimental Cancer Medicine at the Northern Institute for Cancer Research and lead investigator for the phase I study at the Freeman Hospital, Newcastle, said: “ETS2101 derives from an interesting new approach to drug discovery known as network pharmacology. We are pleased to be involved in the first phase of clinical trials evaluating this drug as a potential treatment for cancer.”

e-Therapeutics’ CEO, Professor Malcolm Young, added: “The initiation of a second trial with ETS2101 reflects the growing momentum in our clinical development programme. We hope that the promising preclinical data supporting this drug will ultimately translate into benefits for patients and look forward to seeing the first findings from cancer trials later this year.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

e-Therapeutics Provides Update on Progress of ETS2101 Cancer Trials
Interim data from the trials are expected in H1 2013.
Monday, December 24, 2012
e-Therapeutics’ ETS2101 Enters Phase I Clinical Trial in Brain Cancer
First findings are expected in late 2012.
Wednesday, June 20, 2012
Scientific News
New Gene Therapy for Vision Loss From a Mitochondrial Disease
NIH-funded study shows success in targeting mitochondrial DNA in mice.
Predictive Model for Breast Cancer Progression
Biomedical engineers have demonstrated a proof-of-principle technique that could give women and their oncologists more personalized information to help them choose options for treating breast cancer.
Specific Variations in RNA Splicing Linked to Breast Cancer
Researchers have identified cellular changes that may play a role in converting normal breast cells into tumors. Targeting these changes could potentially lead to therapies for some forms of breast cancer.
Gene Expression: A Snapshot of Stem Cell Development
New genes found that regulate development of stem cells.
Assessing Cancer Patient Survival and Drug Sensitivity
RNA editing events another way to investigate biomarkers and therapy targets.
Editing Genes to Create HIV Killers
Seattle scientists have managed to genetically transform human cells in the lab from HIV targets to HIV killers, and the technique could have implications for cancer and other diseases.
Researchers Disguise Drugs As Platelets to Target Cancer
Researchers have for the first time developed a technique that coats anticancer drugs in membranes made from a patient’s own platelets.
A New Single-Molecule Tool to Observe Enzymes at Work
A team of scientists at the University of Washington and the biotechnology company Illumina have created an innovative tool to directly detect the delicate, single-molecule interactions between DNA and enzymatic proteins.
Milestone Single-Biomolecule Imaging Technique May Advance Drug Design
The first nanometer resolved image of individual tobacco mosaic virions shows the potential of low-energy electron holography for imaging biomolecules at a single particle level; a milestone in structural biology and a potential new tool for drug design.
Opening the Door to Safer, More Precise Cancer Therapies
New method regulates when, and how strongly, cancer-killing therapeutic T cells are activated.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos